PLGA and cancer: a comprehensive patent-based review on the present state of art [0.03%]
PLGA与癌症：一项基于专利的现状综合回顾
Venessa Nath,Mohini Singh,Bani Kumar Jana et al.
Venessa Nath et al.
Poly (lactic-co-glycolic acid) (PLGA) is a highly efficient biodegradable polymeric nanoparticle (NP). Owing to its low toxicity, controlled and sustained release qualities, and biocompatibility with tissue and cells, the US FDA has approve...
Developments in research and commercialization of PI3K and AKT targets: a patent-based landscape [0.03%]
PI3K和AKT靶点的研发及商业化进展：基于专利的分析landscape应译为概况或景观，此处用概况更合适
中文标题：PI3K和AKT靶点的研发及商业化进展：基于专利的概况
Hai-Long Zhang,Zhaochen Lin,Ying Zhang
Hai-Long Zhang
PI3K and AKT signaling pathway has been linked to the pathophysiology of various diseases. This pathway has emerged as a crucial therapeutic strategy for cancer and other diseases. To better understand recent development of PI3K and AKT, a ...
Hermann A M Mucke
Hermann A M Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development. ...
Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs [0.03%]
美国专利局关于重复授权相互矛盾的裁决危及通用名药和生物类似药
Sarfaraz K Niazi
Sarfaraz K Niazi
Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampered the entry of generic and biosimilar drugs...
From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions [0.03%]
从保健补充剂到超级细菌：益生菌专利空白如何推动抗生素抗药性及CRISPR-Cas解决方案
Absar Talat,Asad U Khan
Absar Talat
Ruqaiyyah Siddiqui,David Lloyd,Naveed Ahmed Khan
Ruqaiyyah Siddiqui
Primary Amoebic Meningoencephalitis (PAM) is a severe and often fatal infection caused by the free-living amoebae Naegleria fowleri. This condition typically results from exposure to contaminated warm freshwater/inadequately treated recreat...
Esterase responsive release of anti-cancer agents from conjugated lipid nanocarrier and the regulatory considerations [0.03%]
酯酶响应释放连接的脂质纳米载体中的抗癌药物及其监管考虑因素
Priya Varpe,Ramesh Joga,Gayatri Aglave et al.
Priya Varpe et al.
The release of active agents in tumors rather than normal tissues, limits systemic exposure and toxicities. Targeting over-expressed esterase enzyme in the tumor microenvironment can selectively release immune-active agents like Programmed ...
Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency [0.03%]
通过人工智能、机器学习和专利来催化癌症药物发现的创新
Melody Okereke,Samson Ayorinde Oni,Zainab Ashimiyu-Abdusalam et al.
Melody Okereke et al.
Liraglutide innovations: a comprehensive review of patents (2014-2024) [0.03%]
利拉鲁肽创新专利综述(2014-2024)
Ajay Pandey,Amit Kumar Goyal
Ajay Pandey
Type-2 diabetes mellitus (T2DM) is a complicated long-term disorder associated with metabolism that is identified by insulin resistance, imbalance in glucose regulation and reduced secretion of insulin. GLP-1(Glucagon-like peptide-1) is an ...
3D-printed immediate release solid dosage forms: a patent evaluation of US11622940B2 [0.03%]
用于US11622940B2专利评估的3D打印即释固体制剂形式
Akshay Sharma,Ritu Rathi,Sanchay Sharma et al.
Akshay Sharma et al.
Three-dimensional (3D) printing is one of the most flexible technologies for preparing tablets, offering controlled drug release profiles. The current patent describes the preparation of immediate-release 3D-printed tablets of hydrochloroth...